![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Genentech Files Second Complaint Over Amgen’s Avastin Biosimilar
Genentech Files Second Complaint Over Amgen’s Avastin Biosimilar
October 26, 2017
Genentech filed a second sealed complaint in Delaware against Amgen over its biosimilar for Avastin (bevacizumab).
Genentech filed a sealed complaint earlier this month in the same jurisdiction claiming Amgen’s Mvasi (bevacizumab-awwb) infringed on 24 patents.
The new complaint adds a 25th patent to the claim.
Two weeks ago, Amgen asked the U.S. District Court for the Central District of California for a declaratory judgment that Mvasi does not violate any of Genentech’s 27 Avastin-related patents.
Upcoming Events
-
21Oct